

**MOLECULAR CHARACTERIZATION OF *PLASMODIUM FALCIPARUM*
RESISTANT GENES TO CHLOROQUINE AND SULPHADOXINE-PYRIMETHAMINE
IN CHILDREN WITH UNCOMPLICATED MALARIA IN LAGOS**

A thesis submitted to the School of Postgraduate Studies,
University of Lagos, Nigeria in partial fulfillment of the requirement for
the award of Doctor of Philosophy (Ph.D.)
Degree in Medical Parasitology

BY

OLADOSU, OLADIPO OLARINRE

B.Sc. (Hons.), M.Sc. (UNILAG)

JUNE, 2011

UNIVERSITY OF LAGOS
SCHOOL OF POST GRADUATE STUDIES
CERTIFICATION

This is to certify that the thesis:

“Molecular Characterization of *Plasmodium falciparum* Resistant Genes to Chloroquine and Sulphadoxine-Pyrimethamine in Children with Uncomplicated Malaria in Lagos”

Submitted to the school of Postgraduate Studies, University of Lagos

For the award of the degree of

DOCTOR OF PHILOSOPHY (Ph.D.)

is a record of original research work carried out

By

OLADOSU, OLADIPO OLARINRE

in the Department of Medical Microbiology and Parasitology

DECLARATION

**MOLECULAR CHARACTERIZATION OF *PLASMODIUM FALCIPARUM*
RESISTANT GENES TO CHLOROQUINE AND SULPHADOXINE-PYRIMETHAMINE
IN CHILDREN WITH UNCOMPLICATED MALARIA IN LAGOS**

BY

OLADOSU, OLADIPO OLARINRE

THIS IS TO CERTIFY THAT THIS RESEARCH WORK WAS CARRIED OUT

BY

OLADOSU, OLADIPO OLARINRE, UNDER THE SUPERVISION

1. SUPERVISOR

.....
Dr. Wellington A. Oyibo

Department of Medical Microbiology
and Parasitology
College of Medicine,
University of Lagos, Idi-Araba, Lagos
Nigeria

2. SUPERVISOR

.....
Prof. A.F. Fagbenro-Beyioku

Department of Medical Microbiology
and Parasitology
College of Medicine
University of Lagos, Idi-Araba, Lagos
Nigeria

DEDICATION

This thesis is dedicated to God Almighty, my Parents (Deacon and Mrs .J. Oladosu), my siblings and my wife.

ACKNOWLEDGEMENTS

I acknowledge the goodness and mercies of Jesus Christ over my life and family; To Him only be the glory. My sincere appreciation goes to my supervisor, who has been my father and brother, Dr Wellington Oyibo, for his prayers, time, advice, moral and financial support, never give up attitude and useful suggestions throughout the course of my postgraduate studies. I also want to acknowledge the contributions of my co-supervisors and mother, Prof. A.F. Fagbenro-Beyioku whose advice and scientific inputs contributed immensely to the successful completion of this work. The divine favour and the Lord's Promotion will never cease in their lives. I am also greatly indebted to Dr Collin Sutherland, for providing space and making available all the reagents and equipment for my pre-doctoral training at the London School of Hygiene and Tropical Medicine, London UK, where the molecular aspect of this project was carried out. I also appreciate their generous support and encouragement throughout my stay in London. Indeed, I appreciate Mary Dr Racheal Hallet and her colleagues in the lab (London School of Hygiene and Tropical Medicine, London) for their technical. It is imperative to appreciate the contribution and support of the Medical Director, Dr Chiara and the entire Staff of St Kizito Primary Health Centre Lagos. St Kizito gave the approval for sample to be collected.

I also want to thank Prof. A.O. Coker, Prof. S.A. Omilabu, my Honourable Head of Department, Prof. F.T. Ogunsola for all her support and all other academic and non-academic staff members in the Department of Medical Microbiology and Parasitology for their support, encouragement throughout the period of my studies.

I acknowledge the contributions of my colleagues and friends, Dr Ojuromi Oladele, Dr Agomo Chimere, Chika Okangba and Salami Adekunle, etc. Your friendly disposition cannot be forgotten and in no small way, thanks for those inspirational words that motivated me.

I appreciate my mother (Mrs Victoria Oladosu) and father (Deacon Joshua Oladosu) for their daily prayers and their words of encouragement throughout the programme and for directing me to a wonderful future. To my brothers: Julius Oladosu, Daramola, Tunji Oladosu, Olawunmi Oladosu, Soji Oladosu, Lanre Oladosu, my wife (Folashade Oladosu) and my nephews (Femi Oladosu and Bode Oladosu) and my nieces (Damilola Oladosu, Mercy Oladosu and others too numerous to mention.

TABLE OF CONTENTS

TITLE PAGE	(i)
CERTIFICATION	(ii)
DECLARATION	(iii)
DEDICATION	(iv)
ACKNOWLEDGEMENTS	(v)
TABLE OF CONTENTS	(vii)
LIST OF TABLES	(xi)
LIST OF FIGURES	(xii)
ABSTRACT	(xiii)
CHAPTER ONE	1
1.0 GENERAL INTRODUCTION	1
1.1 Background of Study.....	1
1.2 Statement of Problem.....	3
1.3 Aim of Study.....	5
1.4 Specific Objectives.....	5
1.5 Significance of the Study.....	6
1.6 Limitations of Study.....	7
1.7 Operational Definition of Terms.....	7
1.8 List of Abbreviations.....	8
CHAPTER TWO	11
2.0 LITERATURE REVIEW	11
The Malaria Parasite.....	11
Life Cycle of the Malaria Parasite.....	11
Malaria Prevalence in Sub-Saharan Africa.....	12
Malaria Prevalence in Nigeria.....	13
Clinical Features of Malaria in Infants and Children.....	15
Uncomplicated or Mild Malaria.....	16
Severe/Complicated Malaria.....	17
Fever.....	17
Cerebral Malaria.....	19

Anaemia.....	21
Respiratory Distress and Metabolic Acidosis.....	23
Hypoglycaemia.....	23
Seizures.....	24
Immune Response.....	26
Diagnosis.....	27
Malaria Treatment.....	28
Antimalarial Drugs.....	28
Antibiotics used as antimalarials drugs.....	39
Management of uncomplicated malaria in children.....	39
Management of complicated malaria in children.....	41
Available ACTs in the Nigerian Markets and their Combinations.....	42
Antimalarial Drug Resistance.....	43
Mechanism of Antimalarial Drug Resistance.....	44
<i>Pfcr</i>	44
<i>Pfmdr1</i>	47
<i>Dhps</i> and <i>Dhfr</i>	49
CHAPTER THREE.....	53
3.0 MATERIALS AND METHODS.....	54
3.1.1. Study Area.....	54
3.1.2 Study Population and Designs.....	54
3.1.3. Ethical Consideration.....	55
3.1.4. Sample Collection.....	55
3.1.5. Sample Size.....	55
3.2.1. Equipment and Reagents.....	56
3.3.1. Laboratory Work Up.....	57
3.3.2. Laboratory Diagnosis of Malaria Parasite (Microscopy).....	57
3.3.3. Molecular Genotyping.....	58
3.3.3.1. Extraction of DNA from Samples Collected on Filter Paper.....	58
3.3.3.2. Genotyping of the <i>Pfcr</i> locus.....	58

3.3.3.3.	<i>Pfmdr1</i> , <i>Pfdhfr</i> and <i>Pfdhps</i> Amplification.....	58
3.3.3.4.	<i>Pfmdr1</i> Genotyping.....	60
3.3.3.5.	<i>Pfmdr1</i> Fragment 1 (FR1) Amplification.....	61
3.3.3.6.	<i>Pfmdr1</i> Fragment 3 (FR3) Amplification.....	61
3.3.3.7.	<i>Pfmdr1</i> Fragment 4 (FR4) Amplification.....	62
3.3.3.8.	<i>Pfdhfr</i> and <i>Pfdhps</i> Genotyping.....	63
3.3.3.9.1.	<i>Pfdhfr</i> Genotyping.....	63
3.3.3.9.2.	<i>Pfdhps</i> Genotyping,.....	64
3.4.	Agarose gel Electrophoresis.....,,.....	64
3.5.	Amplified DNA Purification and Sequencing.....	65
3.5.1.	Purification.....	65
3.5.2.	Sequencing.....	66
3.6	Genotyping and Sequence Analysis.....	67
3.6.1	Genotyping.....	67
3.6.2.	Sequence Analysis.....	67
3.7.	Statistical Analysis.....	67
CHAPTER FOUR		68
4.0. RESULTS		69
4.1.	Malaria Prevalence in Children.....	69
4.2.	Genotyping of the <i>Pfcrt</i> locus.....	78
4.3.	Amplified <i>Pfmdr1</i> Alleles (FR1, FR2 and FR3).....	84
4.3.1.	Prevalence of Polymorphisms at the <i>Pfmdr-1</i> Loci.....	84
4.3.2.	Combined analysis of <i>Pfcrt</i> and <i>Pfmdr1</i> (FR1, FR3 and FR4) Haplotypes.....	84
4.3.3.	Parasitaemia and <i>Pfcrt</i> Haplotypes.....	91
4.3.4.	Parasitaemia and <i>Pfmdr1</i> (FR1, FR3 and FR4) Haplotypes.....	91
4.4.	Amplified <i>Dhfr</i> and <i>Dhps</i> Alleles.....	94
4.4.1.	Prevalence of <i>Pfdhfr</i> and <i>Pfdhps</i> genotypes.....	94
4.4.2.	Parasitaemia and <i>Dhfr</i> Haplotypes.....	102
4.4.3.	Parasitaemia and <i>Dhps</i> Haplotypes.....	102
CHAPTER FIVE		105

5.0. DISCUSSION.....	105
5.1 CONTRIBUTIONS TO KNOWLEDGE.....	118
CHAPTER SIX.....	119
6.0. CONCLUSION	119
7.0 REFERENCES.....	120

LIST OF TABLES

Table 1. Sex, Age and Temperature of the Children enrolled.....	70
Table 2. Sex, Age, Temperature and Parasite Density of the Malaria Positive Children.....	71
Table 3. Prevalence and Intensity of <i>Plasmodium</i> in the Different Age Groups.....	72
Table 4. Prevalence of Point Mutations in <i>Pfmdr1</i> (FR1, FR3 and FR4) in a cohort of Children Studied.....	89
Table 5. Combined analysis of 21 isolates in <i>Pfcrt</i> and <i>Pfmdr1</i> (FR1, FR3 and FR4) haplotypes.....	90
Table 6. Parasitaemia and <i>Pfcrt</i> haplotypes.....	92
Table 7. Parasitaemia and <i>Pfmdr1</i> Fragment 1, 3 and 4 Haplotypes in a Cohort of Malaria Positive Children.....	93
Table 8. Prevalence of SP mutations in <i>Plasmodium falciparum</i> isolates from children in Lagos, Nigeria.....	100
Table 9. Frequency of haplotypes in <i>Dhfr</i> and <i>Dhps</i> genes in <i>Plasmodium falciparum</i> isolates of children in Lagos, Nigeria.....	101
Table 10. Haplotypes reported in <i>Dhfr</i> and <i>Dhps</i> genes	102
Table 11. Parasitaemia and <i>Dhfr</i> haplotypes.....	103
Table 12. Parasitaemia and <i>Dhps</i> haplotypes.....	104

LIST OF FIGURES

Figure 1. Distribution of Parasitaemia in the studied children (0-12yrs).....	74
Figure 2. Distribution of Parasitaemia in 0-≤1 and >1-12yrs.....	75
Figure 3. Distribution of Parasitaemia in Age Group II (0-≤5 and >5-12yrs.....	76
Figure 4. Distribution of Parasitaemia in Age Group I (1-3m, 4-6m, 7-9m and 10-12m).....	77
Figure 5. <i>Pfcrt</i> Haplotypes frequencies among 119 falciparum isolate.....	79
Figure 6. <i>Pfcrt</i> Allelic data for Cycling A.FAM, Cycling A.JOE, Cycling A.ROX.....	80
Figure 7. Wild (CVMNK) <i>Pfcrt</i> Cycling for FAM (Wild haplotypes).....	81
Figure 8. Mutant (CVIET) <i>Pfcrt</i> Cycling JOE (Mutant haplotypes).....	82
Figure 9. Non- fluorescence (SVMNT) <i>Pfcrt</i> Cycling for ROX (Asian haplotypes).....	83
Figure 10. Sample of PCR products for <i>Pfmdr1</i> fragment 1.....	85
Figure 11. Sample of PCR products for <i>Pfmdr1</i> fragment 3.....	86
Figure 12. Sample of PCR products for <i>Pfmdr1</i> fragment 4.....	87
Figure 13. Sequenced <i>Pfmdr1</i> genes showing Chromatogram.....	88
Figure 14 Sample of PCR products for <i>Dhfr</i> gene.....	95
Figure 15. Sample of PCR products for <i>Dhps</i> gene.....	96
Figure 16. Sequenced <i>Dhfr</i> genes showing Chromatogram.....	97

ABSTRACT

Malaria is one of the major causes of morbidity and mortality in young children in sub-Saharan Africa where it presents primarily with fever. The reports of malaria prevalence in Nigerian children are divergent with wide variation in prevalence reports despite the scaling-up of malaria control in many countries, including Nigeria. Despite the change in the National antimalarial treatment policy from Chloroquine (CQ) and Sulphadoxine-pyrimethamine (SP) to artemisinin combination therapies (ACTs), CQ and SP are still frequently used in health facilities in the general population because it is cheap, affordable and accessible. Resistance to CQ and SP has contributed to increase mortality caused by *Plasmodium falciparum* infections. The continuous use of non-efficacious antimalarials will consequently result in an increase in antimalarial- resistant *Plasmodium* parasites which could pose a threat to the partner drugs to the Artemisinin such as (Amodiaquine, Mefloquine etc). Genetic markers to predict *Plasmodium* parasites' resistance especially for single nucleotide polymorphism (SNPs) have the potential to be employed in an integrated fashion to provide timely information that is useful to policy makers on *P falciparum* resistance to antimalaria. Children less than 12years old, who presented with documented fever or history of fever in the last 24 hours between July 2007 and April 2008 were enrolled in this study. Of the 1211 children (<12years) enrolled, 251(20.7%) were slide positive for malaria parasites. Children in the age groups $0 \leq 1$ and $>1-12$ years had a prevalence of 11% and 5.8% respectively ($P=0.001$). While children in the age group $0 \leq 5$ and $>5-12$ years had malaria prevalence of 16.9% and 42.1% respectively ($P=0.001$). Of the malaria positive children 33.9% had parasitaemia of less than 500p/ μ l ($P=0.001$). This indicated a shift in malaria prevalence from the usually reported $0 \leq 5$ years to the $>5-12$ years old children. The occurrence of point mutations and haplotypes were investigated in DNA obtained from blood samples of slide positive children by assaying for *Plasmodium falciparum* chloroquine resistance transporter (*Pfcr*t) and *Plasmodium falciparum* multi-drug resistance (*Pfmdr*1) genes associated with CQ and other 4-aminoquinolines resistance. The frequency of the mutant *Pfcr*t haplotype, CVIET, was 91.6% while, the frequency of *Pfmdr*1 in the positive microscopy samples was

62.2% and 69.0% for codon Y86 and F184 respectively. No mutation was seen at codons 1034, 1042 and 1246 of the *Pfmdr1* genes in this study. The combined *Pfcrt* and *Pfmdr1* haplotypes showed that most of the malaria positive children had CVIET + YFSND haplotypes (61.9%). There was no association between parasitaemia and *Pfcrt* and *Pfmdr1* haplotypes. The high prevalence of the mutant genes (CVIET) seen among this children could limit the already poor efficacy of the partner drugs to the Artemisinin. Thus, the continuous use of CQ and other 4-aminoquinolines when used as monotherapy in Lagos State could increase the frequency of mutations in *Pfcrt* and *Pfmdr1* genes. Sequenced results of the amplified *Dihydrofolate reductase* (*Dhfr*) and *Dihydropteroate synthase* (*Dhps*) genes for SNPs showed mutations at codons 108 (96.5%), 59 (92.9%) and 51 (94.7%). Four *Dhfr* haplotypes (ACIRNVI, ACICNVI, ACNCNVI and ACNCSVI) and eleven *Dhps* haplotypes (ISGKAA, VAGKGS, VAGKAA, IAGKAS, ISAKAA, IAAKAA, ISGKGA, IFGKAS, IAGKAA, VSGKGS and ISGKAS) were grouped. The grouped data showed that most of the isolates (92.9%) had the triple *Dhfr* mutation (51I, R59 and 108N), while the majority of the isolated *P. falciparum* in the *Dhps* gene had mutation at codon G437 (96.6%). The combined haplotypes assessment showed that ACIRNVI + ISGKAA (quadruple mutation) had the highest occurrence (56.7%). There was no mutation at V16, R50 and L164 of the *Dhfr* gene and at E540 of the *Dhps* gene. These reports showed a high frequency of mutations in *Dhfr* and *Dhps* genes in Nigeria. Furthermore, it provided information on haplotypes and its distribution on clinical samples from children in Lagos. The continuous use of SP as monotherapy against malaria and the reported high frequency of mutations in *Dhfr* and *Dhps* genes could compromise the efficacy of SP-artesunate combination.